Editas Medicine And IDT Highlight Publication In Nature Communications Of Research Data Supporting Use Of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, In Researching Potential Of Gene-Edited Cell Medicines